Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19

Br J Haematol. 2020 Jul;190(2):e73-e76. doi: 10.1111/bjh.16863. Epub 2020 Jun 4.
No abstract available

Keywords: BTK inhibitors; CLL; COVID-19.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors
  • Aged
  • Aged, 80 and over
  • Benzamides / therapeutic use
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections / complications*
  • Female
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / complications*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazines / therapeutic use
  • Pyrazoles / therapeutic use
  • Pyrimidines / therapeutic use
  • SARS-CoV-2

Substances

  • Benzamides
  • Protein Kinase Inhibitors
  • Pyrazines
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Agammaglobulinaemia Tyrosine Kinase
  • acalabrutinib